This time may be different

Nature Biotechnology

Volumn 34, Issue 1, 2016, Pages 25-30

  Booth, Bruce L ^a  

^a 400 Technology Square   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIVIRUS AGENT; CENTOXIN; CHIMERIC ANTIGEN RECEPTOR; IDELALISIB; LIPID; NEW DRUG; NUCLEOTIDE; RECOMBINANT PROTEIN;

ALZHEIMER DISEASE; BIOTECHNOLOGY; CAPITAL; CELL THERAPY; COMBINATORIAL CHEMISTRY; CRYSTALLOGRAPHY; DIABETES MELLITUS; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL GENOMICS; FUNDING; GENE THERAPY; GENETIC ASSOCIATION; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATION; INVESTMENT; LYMPHOMA; MARKET; NOTE; OBESITY; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; REIMBURSEMENT; TANDEM MASS SPECTROMETRY;

BIOTECHNOLOGY; INVESTMENTS;

EID: 84953790705     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3452     Document Type: Note

References (7)

1. Ernst & Young. Biotech '92: Promise to Reality. Ernst & Young Annual Biotech Report. 1992 (Ernst & Young, New York, 1992).
2. Slud, M. Boom time for biotech. CNNMoney (22 February 2000). http://money.cnn.com/2000/02/22/companies/biotech/
3. Thomas, D. & Wessel, C. Emerging therapeutic company investment and deal trends (Biotechnology Industry Organization, 11 June 2015). https://www.bio.org/sites/default/files/BIO%20Emerging%20Therapeutic%20Company%20Report%20June%2011%202015.pdf
4. Ernst & Young. Beyond Borders: Reaching New Heights. Ernst & Young Annual Biotech Report 2015 (Ernst & Young, New York, 2015). http://www.ey.com/Publication/vwLUAssets/EY-beyond-borders-2015/$FILE/EY-beyond-borders-2015.pdf
5. Schulze, U. et al. Nat. Rev. Drug Discov. 13, 331-332 (2014).
6. Smietana, K. et al. Nat. Rev. Drug Discov. 14, 455-456 (2015).
7. Booth, B. et al. Improving the Pharma Research Pipeline McKinsey Quarterly, Web Exclusive August 2004 (Mckinsey, New York, 2004)